A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy

NCT06642909 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Membranous Nephropathy

Interventions

DRUG: Zuberitamab 600mg
DRUG: Zuberitamab 1000mg
DRUG: cyclosporine

Sponsor

BioRay Pharmaceutical Co., Ltd.